Investor Presentaiton

...with consistent financial performance over the years (cont'd)... ROE 7.6% 2.6% FY17 19.0% 14.8% ROCE (%) 26.9% FY18 FY19 FY20 FY21 Net Debt to EBITDA (x) 1.9 FY17 1 0.5 FY18 ©2021 - Marksans Pharma Limited, All Rights Reserved. 10.4% 3.2% 24.6% 19.1% 32.6% FY17 FY18 FY19 FY20 FY21 Fixed Asset Turnover Ratio (x) * 4.4 4 3.6 3.3 2.9 -0.4 -0.6 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 * Includes Tangible net fixed assets, CWIP and net Intangibles 21

View entire presentation